SCHEMBL2795656

SCHEMBL2795656

COc1ccc(NC(C)=O)c(OCCCBr)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
HSD17B1 P14061 1/20 0.53
HSD17B2 P37059 1/20 0.53
MAPT P10636 4/20 0.50
MEN1 O00255 1/20 0.50
PKM P14618 1/20 0.50
KMT2A Q03164 1/20 0.50
HPGD P15428 2/20 0.49
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
BRD4 O60885 1/20 0.47
PTK2 Q05397 1/20 0.47
CYP1A1 P04798 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP1B1 Q16678 1/20 0.47
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8522611 0.88 ALDH1A1 (0.55) ALDH1A1HSD17B1HSD17B2MAPTMEN1
SCHEMBL31372094 0.84 ALDH1A1 (0.48) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL2796904 0.84 ALDH1A1 (0.48) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL2191052 0.81 HSD17B1 (0.75) ALDH1A1HSD17B1HSD17B2MAPTMEN1
SCHEMBL30622065 0.81 HSD17B1 (0.75) ALDH1A1HSD17B1HSD17B2MAPTMEN1
SCHEMBL3959073 0.78 FLT3 (0.54) ALDH1A1HSD17B1HSD17B2MAPTMEN1
SCHEMBL3860865 0.78 ALDH1A1 (0.54) ALDH1A1HSD17B1HSD17B2MAPTMEN1
SCHEMBL3815180 0.78 ALDH1A1 (0.53) ALDH1A1HSD17B1HSD17B2MAPTMEN1
SCHEMBL3860431 0.78 ALDH1A1 (0.53) ALDH1A1HSD17B1HSD17B2MAPTMEN1
SCHEMBL4214562 0.78 ALDH1A1 (0.53) ALDH1A1HSD17B1HSD17B2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010077915-A1 NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-07-08 WO disclosed
WO-2010077915-A1 NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-07-08 WO disclosed
US-20100168080-A1 NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS KHAMRAI UTTAM 2010-07-01 US disclosed
US-20100168080-A1 NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS KHAMRAI UTTAM 2010-07-01 US disclosed
US-20100168080-A1 NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS KHAMRAI UTTAM 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168080-A1 NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS CCR1, CCR5, CCR3 ALDH1A1 1547/4885HSD17B1 3141/4885HSD17B2 3673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.